- Home
- PLX vs AMRN Comparison
PLX vs AMRN Comparison
Compare PLX & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- AMRN
- Stock Information
- Founded
- PLX 1993
- AMRN 1989
- Country
- PLX Israel
- AMRN Ireland
- Employees
- PLX N/A
- AMRN N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- AMRN Health Care
- Exchange
- PLX Nasdaq
- AMRN Nasdaq
- Market Cap
- PLX 160.2M
- AMRN 189.2M
- IPO Year
- PLX 1998
- AMRN 1993
- Fundamental
- Price
- PLX $2.33
- AMRN $0.57
- Analyst Decision
- PLX
- AMRN Buy
- Analyst Count
- PLX 0
- AMRN 1
- Target Price
- PLX N/A
- AMRN N/A
- AVG Volume (30 Days)
- PLX 553.9K
- AMRN 1.7M
- Earning Date
- PLX 03-13-2025
- AMRN 02-27-2025
- Dividend Yield
- PLX N/A
- AMRN N/A
- EPS Growth
- PLX N/A
- AMRN N/A
- EPS
- PLX N/A
- AMRN N/A
- Revenue
- PLX $45,667,000.00
- AMRN $241,021,000.00
- Revenue This Year
- PLX N/A
- AMRN N/A
- Revenue Next Year
- PLX $90.00
- AMRN N/A
- P/E Ratio
- PLX N/A
- AMRN N/A
- Revenue Growth
- PLX N/A
- AMRN N/A
- 52 Week Low
- PLX $0.82
- AMRN $0.43
- 52 Week High
- PLX $2.36
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- PLX 78.72
- AMRN 62.67
- Support Level
- PLX $2.11
- AMRN $0.43
- Resistance Level
- PLX $2.36
- AMRN $0.49
- Average True Range (ATR)
- PLX 0.12
- AMRN 0.04
- MACD
- PLX 0.00
- AMRN 0.01
- Stochastic Oscillator
- PLX 94.23
- AMRN 99.71
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.